Skip to main content
. 2018 Oct 17;10(10):387. doi: 10.3390/cancers10100387

Figure 6.

Figure 6

Intravenous morphine usage and pain assessment. Ch14.18/CHO-dependent pain toxicity was evaluated by systematic assessments of i.v. morphine usage (A,C,D) and pain scores (B) in every treatment cycle during antibody administration (LTI, 10 days) as described in “Materials and Methods”. (A) Usage of i.v. morphine in μg/kg/d was determined daily per pt and cycle and presented as mean ± SEM. When error bars are not visible, they are covered by the symbol; (B) Pain assessment scores were determined daily per pts and cycle using two validated age-adapted pain score systems. Values represent mean maximum pain scores ± SEM; (C) Comparison of i.v. morphine usage in every cycle on d8 (i.e., d1 of ch14.18/CHO infusion) in HACA-negative pts (closed circles) and pts with neutralizing (closed triangles) and non-neutralizing HACA (open circles); (D) Daily i.v. morphine usage in cycle 3 in HACA-negative pts (closed circles) and pts with neutralizing (closed triangles) and non-neutralizing HACA (open circles). Data represent mean ± SEM. When error bars are not visible they are covered by the symbol. t-test or Mann-Whitney Rank Sum test. (A) *** p < 0.001 vs. d1, cycle 1; §§§ p < 0.001 vs. d1, cycle 2, 3, 4 and 5; (B) ** p < 0.01 vs. d1, cycle 1; §§§ p < 0.001 vs. d1, cycle 2, 3, 4 and 5.